OPTILONE - JP OPHTHALMICS
Jamjoom Pharma

(Fluorometholone 0.1%)

COMPOSITION
Each ml contains:
Fluorometholone 1 mg with: Liquifilm (polyvinyl alcohol) 14 mg, benzalkonium chloride 0.04 mg, edetate disodium, chloride, sodium phosphate monobasic, sodium phosphate dibasic, polysorbate 80, and water

PHARMACOLOGY
Inhibition of the inflammatory response to inciting agents of mechanical, chemical or immunological nature. No generally accepted explanation of this steroid property has been advanced. Adrenocorticosteroids and their derivatives are capable of producing a rise in intraocular pressure. In clinical studies on patients eyes treated with both dexamethasone and fluorometholone, fluorometholone demonstrated a lower propensity to increase intraocular pressure than did dexamethasone.

INDICATION
- Acute superficial herpes simplex keratitis.
- Fungal diseases of ocular structures.
- Vaccinia, varicella and most other viral diseases of cornea and conjunctiva.
- Tuberculosis of the eye.
- Hypersensitivity to the constituents of this medication.

WARNING
Not for injection into the eye.
This ophthalmic product contains Benzalkonium Chloride as a preservative, which may be deposited in soft contact lenses, therefore this product should not be used while wearing these lenses. These lenses should be removed before application of this product and not re-inserted earlier than 15 minutes after use.
Steroid medication in the treatment of herpes simplex keratitis (involving stroma) requires great caution; frequent slit-lamp microscopy is mandatory.

USE IN PREGNANCY
Safety of the use of topical steroids during pregnancy has not been established.

PRECAUTIONS
As fungal infection of the cornea are particularly prone to develop coincidentally with long-term local steroid applications, fungus invasion must be suspected in any persistent corneal ulceration where a steroid has been used or is in use. Intraocular pressure should be checked frequently.

ADVERSE REACTION
Glaucoma with optic nerve damage, visual acuity or field defects posterior subcapsular cataract formation, secondary ocular infection from pathogens liberated from ocular tissues, perforation of the globe.

DOSAGE AND ADMINISTRATION
1 to 2 drops instilled into the conjunctival sac two to four times daily. During the initial 24 to 48 hours the dosage may be safely increased to 2 drops every hour. Care should be taken not to discontinue therapy prematurely.

PRESENTATION
Optilone Sterile ophthalmics suspension, 5 ml in LDPE bottle

STORAGE
Store at 15°C - 25°C, protect from freezing. One prescription only. Shake well before use.